Cita APA (7a ed.)
Caligiuri, M., Williams, G. L., Castro, J., Battalagine, L., Wilker, E., Yao, L., . . . Guichard, S. M. (2023). FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer. Targeted Oncology, 18(2), 269-286.
Cita Chicago Style (17a ed.)
Caligiuri, Maureen, et al. "FT-6876, a Potent and Selective Inhibitor of CBP/p300, Is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer." Targeted Oncology 18, no. 2 (2023): 269-286.
Cita MLA (9a ed.)
Caligiuri, Maureen, et al. "FT-6876, a Potent and Selective Inhibitor of CBP/p300, Is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer." Targeted Oncology, vol. 18, no. 2, 2023, pp. 269-286.
Precaución: Estas citas no son 100% exactas.